Literature DB >> 26562543

Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease.

Mudasir Maqbool1, Mohammad Mobashir2, Nasimul Hoda3.   

Abstract

Neurodegenerative diseases are among the most challenging diseases with poorly known mechanism of cause and paucity of complete cure. Out of all the neurodegenerative diseases, Alzheimer's disease is the most devastating and loosening of thinking and judging ability disease that occurs in the old age people. Many hypotheses came forth in order to explain its causes. In this review, we have enlightened Glycogen Synthase Kinase-3 which has been considered as a concrete cause for Alzheimer's disease. Plaques and Tangles (abnormal structures) are the basic suspects in damaging and killing of nerve cells wherein Glycogen Synthase Kinase-3 has a key role in the formation of these fatal accumulations. Various Glycogen Synthase Kinase-3 inhibitors have been reported to reduce the amount of amyloid-beta as well as the tau hyperphosphorylation in both neuronal and nonneuronal cells. Additionally, Glycogen Synthase Kinase-3 inhibitors have been reported to enhance the adult hippocampal neurogenesis in vivo as well as in vitro. Keeping the chemotype of the reported Glycogen Synthase Kinase-3 inhibitors in consideration, they may be grouped into natural inhibitors, inorganic metal ions, organo-synthetic, and peptide like inhibitors. On the basis of their mode of binding to the constituent enzyme, they may also be grouped as ATP, nonATP, and allosteric binding sites competitive inhibitors. ATP competitive inhibitors were known earlier inhibitors but they lack efficient selectivity. This led to find the new ways for the enzyme inhibition.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease (AD); Amyloid-beta; Glycogen synthase Kinase-3 (GSK-3); Neurodegenerative diseases (ND); Plaques; Tangles

Mesh:

Substances:

Year:  2015        PMID: 26562543     DOI: 10.1016/j.ejmech.2015.10.018

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  53 in total

1.  Identification of a novel selective and potent inhibitor of glycogen synthase kinase-3.

Authors:  Mahboubeh S Noori; Pooja M Bhatt; Maria C Courreges; Davoud Ghazanfari; Chaz Cuckler; Crina M Orac; Mark C McMills; Frank L Schwartz; Sudhir P Deosarkar; Stephen C Bergmeier; Kelly D McCall; Douglas J Goetz
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-25       Impact factor: 4.249

2.  Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome.

Authors:  Marta Pardo; Eleonore Beurel; Richard S Jope
Journal:  Eur J Neurosci       Date:  2016-11-12       Impact factor: 3.386

3.  PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.

Authors:  Wei-Chun J Hsu; Norelle C Wildburger; Sigmund J Haidacher; Miroslav N Nenov; Oluwarotimi Folorunso; Aditya K Singh; Brent C Chesson; Whitney F Franklin; Ibdanelo Cortez; Rovshan G Sadygov; Kelly T Dineley; Jay S Rudra; Giulio Taglialatela; Cheryl F Lichti; Larry Denner; Fernanda Laezza
Journal:  Exp Neurol       Date:  2017-05-15       Impact factor: 5.330

4.  Radiosynthesis and in Vivo Evaluation of [11C]A1070722, a High Affinity GSK-3 PET Tracer in Primate Brain.

Authors:  Jaya Prabhakaran; Francesca Zanderigo; Kiran Kumar Solingapuram Sai; Harry Rubin-Falcone; Matthew J Jorgensen; Jay R Kaplan; Akiva Mintz; J John Mann; J S Dileep Kumar
Journal:  ACS Chem Neurosci       Date:  2017-05-17       Impact factor: 4.418

Review 5.  Dynamics of diabetes and obesity: Epidemiological perspective.

Authors:  Annette Boles; Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-01-24       Impact factor: 5.187

6.  Neuroprotective Functions for the Histone Deacetylase SIRT6.

Authors:  Shai Kaluski; Miguel Portillo; Antoine Besnard; Daniel Stein; Monica Einav; Lei Zhong; Uwe Ueberham; Thomas Arendt; Raul Mostoslavsky; Amar Sahay; Debra Toiber
Journal:  Cell Rep       Date:  2017-03-28       Impact factor: 9.423

7.  Dual GSK-3β/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimer's Disease Drug Discovery.

Authors:  Xue-Yang Jiang; Ting-Kai Chen; Jun-Ting Zhou; Si-Yu He; Hong-Yu Yang; Yao Chen; Wei Qu; Feng Feng; Hao-Peng Sun
Journal:  ACS Med Chem Lett       Date:  2018-02-09       Impact factor: 4.345

8.  Mechanisms Associated with Type 2 Diabetes as a Risk Factor for Alzheimer-Related Pathology.

Authors:  Men Su; Kambiz Naderi; Nathalie Samson; Ihsen Youssef; Livia Fülöp; Zsolt Bozso; Serge Laroche; Benoit Delatour; Sabrina Davis
Journal:  Mol Neurobiol       Date:  2019-01-25       Impact factor: 5.590

9.  Sulfur-containing therapeutics in the treatment of Alzheimer's disease.

Authors:  Haizhou Zhu; Venkateshwara Dronamraju; Wei Xie; Swati S More
Journal:  Med Chem Res       Date:  2021-01-15       Impact factor: 1.965

10.  β-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade.

Authors:  Fang Zhang; Mary Gannon; Yunjia Chen; Shun Yan; Sixue Zhang; Wendy Feng; Jiahui Tao; Bingdong Sha; Zhenghui Liu; Takashi Saito; Takaomi Saido; C Dirk Keene; Kai Jiao; Erik D Roberson; Huaxi Xu; Qin Wang
Journal:  Sci Transl Med       Date:  2020-01-15       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.